SCHEMBL1885300

SCHEMBL1885300

CC(NC(=O)[C@H](C)c1cccc(C(=O)c2ccco2)c1)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.49
ALDH1A1 P00352 5/20 0.49
PTGS1 P23219 3/20 0.49
PTGS2 P35354 3/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
LMNA P02545 3/20 0.49
CXCR1 P25024 2/20 0.49
CXCR2 P25025 2/20 0.49
RECQL P46063 2/20 0.49
CYP3A4 P08684 2/20 0.49
KDM4E B2RXH2 1/20 0.49
HPGD P15428 1/20 0.49
MAPK1 P28482 1/20 0.49
PMP22 Q01453 1/20 0.49
SLC22A6 Q4U2R8 1/20 0.49
HSD17B10 Q99714 1/20 0.49
CXCL8 P10145 1/20 0.49
THPO P40225 1/20 0.49
HIF1A Q16665 1/20 0.49
HTT P42858 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12660189 1.00 MAPT (0.49) MAPTALDH1A1PTGS1PTGS2SMN1; SMN2
SCHEMBL1885304 1.00 MAPT (0.49) MAPTALDH1A1PTGS1PTGS2SMN1; SMN2
SCHEMBL1884640 0.88 PTGS1 (0.52) MAPTALDH1A1PTGS1PTGS2SMN1; SMN2
SCHEMBL1884642 0.88 PTGS1 (0.52) MAPTALDH1A1PTGS1PTGS2SMN1; SMN2
SCHEMBL11616443 0.86 ALDH1A1 (0.66) MAPTALDH1A1PTGS1PTGS2SMN1; SMN2
SCHEMBL1889984 0.85 ALDH1A1 (0.50) MAPTALDH1A1PTGS1PTGS2SMN1; SMN2
SCHEMBL1889981 0.85 ALDH1A1 (0.50) MAPTALDH1A1PTGS1PTGS2SMN1; SMN2
SCHEMBL1883392 0.82 GLI1 (0.51) MAPTALDH1A1PTGS1PTGS2SMN1; SMN2
SCHEMBL1883395 0.82 GLI1 (0.51) MAPTALDH1A1PTGS1PTGS2SMN1; SMN2
SCHEMBL1888503 0.81 ALDH1A1 (0.46) MAPTALDH1A1PTGS1PTGS2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7939521-B2 2-arylpropionic acid derivatives and pharmaceutical compositions containing them DompePHA.R.MA S.p.A. (IT) 2011-05-10 US claimed
EP-1856031-B1 2-ARYLPROPIONIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE PHA R MA SPA RES & MFG (IT) 2009-02-25 EP claimed
US-20080312293-A1 2-Arylpropionic Acid Derivatives and Pharmaceutical Compositions Containing Them DOMPE' PHA.R.MA.S.P.A. (IT) 2008-12-18 US claimed
US-7939521-B2 2-arylpropionic acid derivatives and pharmaceutical compositions containing them DompePHA.R.MA S.p.A. (IT) 2011-05-10 US disclosed
EP-1856031-B1 2-ARYLPROPIONIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE PHA R MA SPA RES & MFG (IT) 2009-02-25 EP disclosed
US-20080312293-A1 2-Arylpropionic Acid Derivatives and Pharmaceutical Compositions Containing Them DOMPE' PHA.R.MA.S.P.A. (IT) 2008-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312293-A1 2-Arylpropionic Acid Derivatives and Pharmaceutical Compositions Containing Them C3AR1, C5AR2, C5AR1 MAPT 4400/4885ALDH1A1 1262/4885PTGS1 197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.